With respect to the latter, studies to determine the organ‐ and cell‐specific effects of the prospective new anti‐fibrotic therapy nerandomilast—a PDE4B‐specific inhibitor [82, 83]—will be necessary to determine its utility in SSc. The gene discussed is PDE4B; the disease is systemic sclerosis.